EUR/USD likely to find a peak near 1.25: UBS
David Altshuler, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals (NASDAQ:VRTX), recently executed a significant stock sale. On February 20, Altshuler sold 1,111 shares of Vertex common stock at a price of $480 per share, totaling $533,280. The transaction comes as Vertex, now valued at $123.7 billion, trades near its 52-week high of $519.88, reflecting the company’s strong market position and robust financial health score of "GOOD" according to InvestingPro metrics. This transaction was carried out under a pre-established trading plan in accordance with Rule 10b5-1, which he entered into on August 8, 2024. Following the sale, Altshuler retains ownership of 45,019 shares. While this insider sale has attracted attention, InvestingPro data reveals that management has been actively buying back shares, and the company has delivered strong returns over the last five years. For deeper insights into Vertex’s valuation and growth prospects, investors can access 13 additional ProTips and comprehensive analysis through InvestingPro’s detailed research reports.
In other recent news, Vertex Pharmaceuticals Incorporated reported fourth-quarter cystic fibrosis revenues of $2.9 billion, surpassing the consensus estimate of $2.77 billion. This strong performance has contributed to an optimistic outlook for the company, which has provided full-year 2025 revenue guidance between $11.75 billion and $12 billion. The anticipated growth is expected to be driven by new product launches, including Journavx, which is set to be available by the end of February. Analysts from TD Cowen and BMO Capital Markets have expressed confidence in Vertex’s long-term growth prospects, maintaining Buy and Outperform ratings with price targets of $525 and $545, respectively.
Truist Securities also raised its price target for Vertex to $520, citing positive feedback on the launches of Alyftrek and Journavx. RBC Capital Markets adjusted its price target slightly to $408, maintaining a Sector Perform rating, while DA Davidson reaffirmed a Buy rating with a $62 price target. The upcoming retirement of Chief Operating Officer Stuart Arbuckle, effective July 1, 2025, marks a significant leadership transition for Vertex. Analysts have highlighted the company’s robust pipeline and strategic positioning as key factors in its projected growth, with Vertex’s ongoing product launches and pivotal trials expected to support revenue increases through 2030.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.